Community Bank N.A. Boosts Position in Pfizer Inc. (NYSE:PFE)

Community Bank N.A. grew its holdings in shares of Pfizer Inc. (NYSE:PFE) by 0.4% during the 4th quarter, according to its most recent Form 13F filing with the SEC. The firm owned 156,717 shares of the biopharmaceutical company’s stock after buying an additional 638 shares during the period. Community Bank N.A.’s holdings in Pfizer were worth $4,512,000 as of its most recent SEC filing.

Other hedge funds have also recently made changes to their positions in the company. Briaud Financial Planning Inc purchased a new position in shares of Pfizer during the third quarter valued at approximately $30,000. GoalVest Advisory LLC increased its stake in shares of Pfizer by 304.9% during the fourth quarter. GoalVest Advisory LLC now owns 1,077 shares of the biopharmaceutical company’s stock valued at $31,000 after buying an additional 811 shares during the period. Mizuho Securities Co. Ltd. purchased a new position in shares of Pfizer during the third quarter valued at approximately $34,000. VisionPoint Advisory Group LLC increased its stake in shares of Pfizer by 52,350.0% during the third quarter. VisionPoint Advisory Group LLC now owns 1,049 shares of the biopharmaceutical company’s stock valued at $35,000 after buying an additional 1,047 shares during the period. Finally, Tennessee Valley Asset Management Partners purchased a new position in shares of Pfizer during the fourth quarter valued at approximately $36,000. 68.36% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several equities analysts have recently issued reports on PFE shares. Guggenheim assumed coverage on Pfizer in a research note on Friday, February 23rd. They set a “buy” rating and a $36.00 target price on the stock. TD Cowen cut Pfizer from an “outperform” rating to a “market perform” rating and set a $32.00 price target on the stock. in a research note on Thursday, January 4th. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $45.00 price target on shares of Pfizer in a research note on Monday, April 15th. Finally, Argus cut Pfizer from a “buy” rating to a “hold” rating in a research note on Friday, March 22nd. Eleven analysts have rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Hold” and an average target price of $36.33.

Pfizer Stock Down 0.2 %

Shares of NYSE PFE traded down $0.06 during trading on Wednesday, reaching $26.26. The company had a trading volume of 24,501,011 shares, compared to its average volume of 41,887,898. Pfizer Inc. has a 12-month low of $25.23 and a 12-month high of $40.37. The stock has a market cap of $148.70 billion, a PE ratio of 72.94, a P/E/G ratio of 1.18 and a beta of 0.61. The business’s 50-day moving average is $27.05 and its 200 day moving average is $28.50. The company has a quick ratio of 0.69, a current ratio of 0.91 and a debt-to-equity ratio of 0.69.

Pfizer (NYSE:PFE) last released its earnings results on Tuesday, January 30th. The biopharmaceutical company reported $0.10 EPS for the quarter, topping analysts’ consensus estimates of ($0.19) by $0.29. Pfizer had a return on equity of 10.88% and a net margin of 3.62%. The firm had revenue of $14.25 billion for the quarter, compared to analysts’ expectations of $14.37 billion. During the same period in the prior year, the firm posted $1.14 earnings per share. The company’s quarterly revenue was down 41.3% on a year-over-year basis. As a group, equities analysts forecast that Pfizer Inc. will post 2.24 earnings per share for the current fiscal year.

Pfizer Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Friday, June 14th. Stockholders of record on Friday, May 10th will be issued a dividend of $0.42 per share. This represents a $1.68 dividend on an annualized basis and a dividend yield of 6.40%. Pfizer’s payout ratio is currently 466.67%.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.